(Credit: Omnipad)
Insulet Corporation, an insulin pump technology manufacturer, announced positive results from the first feasibility study of the Omnipod Horizon hybrid closed-loop system. The study demonstrated that the Omnipod automated glucose control algorithm performed well, was safe during the day and night for adults with type 1 diabetes, and was very effective at night with minimal hypoglycemia and excellent fasting glucose.
These data were presented today at the 10th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France. Additional studies are underway to further validate the performance in adult and pediatric populations.
Study participants included 24 adults with type 1 diabetes. The 36-hour study 1 included a modified version of Insulet’s Omnipod, a Dexcom continuous glucose sensor, and Insulet’s personalized model predictive control algorithm. Results showed use of the Company’s hybrid closed-loop system was associated with significantly less time spent in hypoglycemic blood glucose range compared to ranges prior to the study. Key findings included patients achieving and remaining in the target blood glucose control range 69 percent of the time over the course of the study and maintaining target blood glucose control 90 percent of the time during the overnight period.
“These very positive results, particularly in the overnight period, demonstrate the potential for the Omnipod Horizon System to improve clinical outcomes in patients with type 1 diabetes,” says Dr. Bruce Buckingham, Professor of Pediatric Endocrinology at the Lucille Salter Packard Children’s Hospital, Stanford University, and Principal Investigator of the study. “This is a safe system providing significant reductions in hypoglycemia both during the day and night, and the system made significant improvements in overnight glucose control, decreasing glucose variability and bringing fasting glucose values into range. These are very positive early findings and I think I speak for the entire team when I say I am excited to see how the Horizon system continues to perform in future clinical studies.”
“We are incredibly excited by the early results of this trial, which demonstrated excellent glucose control and tremendous promise to make a significant impact for patients,” says Shacey Petrovic, President and Chief Operating Officer. “Omnipod allows our users to feel more confident, and to experience improved quality of life and outcomes, and we are thrilled our Omnipod Horizon System is already demonstrating the ability to continue to make a significant impact on improving the lives of people with diabetes.”
